{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Placebo%2C+non-active",
    "query": {
      "intervention": "IV Placebo, non-active"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 78,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Placebo%2C+non-active&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T18:55:37.251Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03524092",
      "title": "A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Mirikizumab SC",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1328,
      "start_date": "2018-10-19",
      "completion_date": "2025-02-17",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 57,
      "location_summary": "Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03524092"
    },
    {
      "nct_id": "NCT00399568",
      "title": "Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Pain",
        "Hysterectomy"
      ],
      "interventions": [
        {
          "name": "IV Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "IV Placebo 100 mL solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 331,
      "start_date": "2006-11",
      "completion_date": "2007-09",
      "has_results": true,
      "last_update_posted_date": "2016-10-21",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00399568"
    },
    {
      "nct_id": "NCT00891761",
      "title": "A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "Chemotherapy-Induced Nausea and Vomiting",
        "Nausea and Vomiting",
        "Solid Tumor Cancer"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "IV casopitant (placebo)",
          "type": "DRUG"
        },
        {
          "name": "IV casopitant (active)",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-09",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2015-04-17",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Robbinsdale, Minnesota",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Robbinsdale",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891761"
    },
    {
      "nct_id": "NCT03312907",
      "title": "A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab-placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard therapy (Including Immunosuppressants)",
          "type": "DRUG"
        },
        {
          "name": "Standard therapy (Excluding Immunosuppressants)",
          "type": "DRUG"
        },
        {
          "name": "Steroid Taper",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 292,
      "start_date": "2018-03-01",
      "completion_date": "2021-07-07",
      "has_results": true,
      "last_update_posted_date": "2025-02-18",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03312907"
    },
    {
      "nct_id": "NCT03617679",
      "title": "Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 79,
      "start_date": "2019-03-06",
      "completion_date": "2026-02-27",
      "has_results": true,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03617679"
    },
    {
      "nct_id": "NCT07079761",
      "title": "Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer.",
          "type": "DRUG"
        },
        {
          "name": "Matching IV Placebo",
          "type": "OTHER"
        },
        {
          "name": "Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-08-04",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07079761"
    },
    {
      "nct_id": "NCT07215273",
      "title": "Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Mould Infection"
      ],
      "interventions": [
        {
          "name": "EL219",
          "type": "DRUG"
        },
        {
          "name": "Active Comparator- IV Antifungal (LAmB or voriconazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-13",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07215273"
    },
    {
      "nct_id": "NCT06236438",
      "title": "Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Livmoniplimab",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 840,
      "start_date": "2024-04-10",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06236438"
    },
    {
      "nct_id": "NCT03640221",
      "title": "Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Ertugliflozin",
          "type": "DRUG"
        },
        {
          "name": "Hydrochlorothiazide 12.5mg",
          "type": "DRUG"
        },
        {
          "name": "Microneurography",
          "type": "DEVICE"
        },
        {
          "name": "SKNA recordings",
          "type": "OTHER"
        },
        {
          "name": "Static Handgrip",
          "type": "OTHER"
        },
        {
          "name": "Post-handgrip forearm vascular occlusion",
          "type": "OTHER"
        },
        {
          "name": "Testing of the Arterial Baroreflex Function",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-09-01",
      "completion_date": "2020-08-31",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03640221"
    },
    {
      "nct_id": "NCT06445075",
      "title": "Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Apitegromab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scholar Rock, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 102,
      "start_date": "2024-05-21",
      "completion_date": "2025-06-17",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-09-19T18:55:37.251Z",
      "location_count": 7,
      "location_summary": "Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Marrero",
          "state": "Louisiana"
        },
        {
          "city": "Norman",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445075"
    }
  ]
}